FX-322 in Adults With Acquired Sensorineural Hearing Loss
Public ClinicalTrials.gov record NCT05086276. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Multicenter Study to Evaluate the Efficacy of FX-322 Administered by Intratympanic Injection in Adults With Acquired Sensorineural Hearing Loss
Study identification
- NCT ID
- NCT05086276
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Frequency Therapeutics
- Industry
- Enrollment
- 142 participants
Conditions and interventions
Interventions
- FX-322 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 11, 2021
- Primary completion
- Dec 29, 2022
- Completion
- Dec 29, 2022
- Last update posted
- Apr 20, 2023
2021 – 2022
United States locations
- U.S. sites
- 26
- U.S. states
- 16
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Trial Site | Tucson | Arizona | 00000 | — |
| Clinical Trial Site | Fresno | California | 00000 | — |
| Clinical Trial Site | Torrance | California | 00000 | — |
| Clinical Trial Site | Colorado Springs | Colorado | 00000 | — |
| Clinical Trial Site | Sarasota | Florida | 00000 | — |
| Clinical Trial Site | Tampa | Florida | 00000 | — |
| Clinical Trial Site | Marrero | Louisiana | 00000 | — |
| Clinical Trial Site | Novi | Michigan | 00000 | — |
| Clinical Trial Site | Omaha | Nebraska | 00000 | — |
| Clinical Trial Site | Albany | New York | 00000 | — |
| Clinical Trial Site | Amherst | New York | 00000 | — |
| Clinical Trial Site | New York | New York | 00000 | — |
| Clinical Trial Site | Winston-Salem | North Carolina | 00000 | — |
| Clinical Trial Site | Cincinnati | Ohio | 00000 | — |
| Clinical Trial Site | Oklahoma City | Oklahoma | 00000 | — |
| Clinical Trial Site | Charleston | South Carolina | 00000 | — |
| Clinical Trial Site | Orangeburg | South Carolina | 00000 | — |
| Clinical Trial Site | Spartanburg | South Carolina | 00000 | — |
| Clinical Trial Site | Dallas | Texas | 00000 | — |
| Clinical Trial Site | Fort Worth | Texas | 00000 | — |
| Clinical Trial Site | San Antonio | Texas | 00000 | — |
| Clinical Trial Site | Murray | Utah | 00000 | — |
| Clinical Trial Site | St. George | Utah | 00000 | — |
| Clinical Trial Site | Norfolk | Virginia | 00000 | — |
| Clinical Trial Site | Richmond | Virginia | 00000 | — |
| Clinical Trial Site | Milwaukee | Wisconsin | 00000 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05086276, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2023 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05086276 live on ClinicalTrials.gov.